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Abstract Based on our earlier studies that defined three strate- 
gic regions in the Type 1 interferon (IFN) molecule associated 
with receptor interactions and biological activity, three IFN re- 
ceptor recognition peptides (IRRP) were synthesized, with amino 
acid sequences CLKDRHD (IRRPI), ESLLEKFYTELYQQL- 
ND (IRRP2) and YFQRITLYLTEKKYSPCA (IRRP3) and ex- 
amined for biological effectiveness. In cell surface receptor bind- 
ing studies, the binding capacity of cells for IFN-as was increased 
in the presence of the IRRPs. Increased receptor occupancy re- 
sulted in increased phosphorylation-activation of the transcription 
factor ISGF3 and enhanced antivirai activity. The potentiating 
effect on IFN-induced growth inhibition was less marked. These 
data suggest hat the IRRPs may influence the biological potency 
of IFN-a by facilitating accessibility to cell surface receptor 
components. The IRRPs may function to increase the number of 
low affinity receptor-ligand interactions necessary to initiate re- 
ceptor oligomerization, thereby catalysing the formation of high 
affinity IFN-receptor complexes. 
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I. Introduction 
Type 1 interferons, IFN-alphas (IFN-~) and -beta (IFN-fl), 
mediate their biological effects on target cells via a high affinity 
interaction with specific cell surface receptors. Several labora- 
tories have provided evidence that the Type 1 IFN receptor is 
multimeric, comprising both peptide [1-3] and glycosphingo- 
lipid [4] components. To date, the sequence of events that char- 
acterize the high affinity interaction between the ligand, IFN, 
and the different receptor components remain unclear. Un- 
doubtly, the relative abundance of different receptor compo- 
nents will determine the sensitivity of cell types for IFNs. More- 
over, there is some evidence to suggest that cells may be varia- 
bly responsive to IFN-~s vs. IFN-fl, dependent on constituent 
components associated with the receptor complex [5]. Although 
the existence of an IFN-fl-specific receptor component, or alter- 
natively, a receptor configuration that favours a high affinity 
interaction with IFN-fl, have not been shown, studies from this 
laboratory indicate that a strategic domain within the Type 1 
IFN molecule, that is different for IFN-~s and IFN-fl, may 
accommodate such differences in receptor interactions [6,7]. 
Recent modelling data [7,8] would suggest that three epitopes 
on the IFN molecule, that have been implicated in influencing 
receptor interactions and biological activity, are accessible on 
the surface of the molecule and may, indeed, function as recep- 
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tor recognition epitopes. The present studies were undertaken 
to examine the influence of three peptides, that correspond 
to these strategic domains, on the biological effects of IFN-~. 
The synthetic peptides used were CLKDRHD (IRRP1), 
ESLLEKFYTELYQQLND (IRRP2) and YFQRITLYL- 
TEKKYSPCA (IRRP3), that correspond to the putative lig- 
and binding domains assigned to amino acid residues 29-35, 
78-95 and 123-140, respectively, of IFN-Con~. Accumulating 
evidence suggests that IFN-~/fl bind to the IFNABR chain [3] 
of the IFNABR/IFNAR1 receptor complex, thereby invoking 
ligand-induced phosphorylation f IFNAR1 [8] and phospho- 
rylation-activation f associated Jak/tyk family kinases [9-11]. 
The phosphorylated-activated multimeric transmembrane 
complex is able to sequester and phosphorylate on tyrosine 
residues a limited panel of related transcription factors, or 
STAT proteins, among them cytoplasmic Stat 1 (p91) and Stat2 
(p113) proteins [12]. Statl and Stat2 dimerize via SH2 domains, 
then translocate to the nucleus and associate with an adaptor 
protein, p48, to form the stable and active transcription com- 
plex, ISGF3, that binds to a specific IFN-stimulated response 
element, ISRE, within the promoter egion of IFN-inducible 
genes. Thus, ligand-induced receptor activation leads to the 
transcriptional induction of a distinct set of genes that define 
the characteristic biological responses effected by 1FNs [13 21]. 
We have shown that the extent of receptor occupancy directly 
correlates with the degree of ISGF3 activation, at least for 
IFN-~s [4]. Since ISGF3 activation effects the transcriptional 
induction of lFN-sensitive genes, there is a direct correlation 
between ISGF3 activation and biological outcome. 
In this report we provide evidence that selected IRRPs influ- 
ence the binding characteristics of IFN-~s such that receptor 
occupancy increases, leading to enhanced ISGF3 activation 
and increased biological activity. 
2. Materials and methods 
2.1. Cell cultures 
Human Burkitt lymphoma Daudi cells, were grown as a suspension 
culture and subcultured inRPMI 1640 medium supplemented with 10% 
FCS. T98G, human glial and MRC-5, human embryonal lung cells 
were grown as monolayers in MEM containing 10% FCS. 
2.2. Interferons, IRRPs and related reagents 
IFN-Con~, as a consensus IFN-c~, was a gift from Amgen Inc. (Thou- 
sand Oaks, CA) and had a specific activity of 3.0 × 10 9 U/mg protein. 
This synthetic variant was designed to represent an average IFN-~, with 
an amino acid chosen at each position along the polypeptide that was 
most frequently represented in the known family of IFN-~s. IFN-~2 
was a gift from Schering Canada Inc. and had a specific activity of 
2 × 108 U/mg protein. Three IRRPs (US & International PCT Applica- 
tion Serial no. PCT/CA93/00279), with amino acid sequences from N- 
to C-terminus of CLKDRHD (IRRP1), ESLLEKFYTELYQQLND 
(IRRP2) and YFQRITLYLTEKKYSPCA (IRRP3) were synthesized, 
using an Applied Biosystems Model 430A Peptide Synthesizer. Peptides 
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were HPLC purified and amino acid composition determined by both 
amino acid analysis and mass spectrometry. A random hexapeptide, 
YVKRVK, was a gift from K. Kain (Department of Microbiology, 
University of Toronto). 
2.3. In vitro assays for antiviral and growth inhibitor)' activities 
The in vitro assays for antiviral and antiproliferative activities have 
been previously described [6]. 
2.4. londination of lFN-~ and cell surjace receptor binding assays 
Labelling of IFN-c~2 or IFN-Con~, with t25I was carried out using the 
chloramine T method [22]. Iondination caused no detectable loss of 
activity. The receptor binding assay for suspension cultures has been 
previously described [23]. With increasing concentrations of [~25I]-li- 
gand in the cellular binding reactions, respective specific binding activ- 
ities corresponding to each [~25I]-ligand concentration were calculated. 
2.5. Covalent crosslinking oJ [12Sl]-IFN-Conl to cell surjace receptors 
Following binding of []25I]-IFN-Con~ to cells at 4°C for 2 h, bound 
IFN was crosslinked to the receptors by reaction with 1 mM disuccin- 
imidyl suberate. Cells were washed with PBS and the receptor-ligand 
complexes extracted with 1% Triton X-100. Soluble extracts were ana- 
lyzed by SDS-PAGE containing 7.5% acrylamide. Gels were dried and 
subjected to autoradiography. 
2.6. Oligonucleotides 
A double-stranded oligonucleotide, r presenting ucleotides -107 to 
-87 of the human 2-5A synthetase gene which contains a functional 
ISRE, was synthesized. The sequence is CCTTCTGAGGAAAG- 
GAAACCA. This oligonucleotide was synthesized with a Sa/I-compat- 
ible linker at the 5' terminus (TCGAC). Gel-purified oligonucleotide 
was mixed with an equimolar amount of its respective complement, 
heated to 65°C for 15 min, and annealed at room temperature for 18 h. 
This preparation was end-labeled for use in electrophoretic mobility 
gel shift assays by T4 polynucleotide kinase in the presence of [y_32p]_ 
ATP. 
2. 7. Extract preparation and electrophoretic mibility shift assay 
( EMSA ) 
Whole cell extracts were prepared from IFN-treated or untreated 
cells as described in [24,25]. Binding reactions for the gel retardation 
assay contained 5' 32p-labeled oligonucleotide, specific competitor 
DNA, and whole cell extract as indicated in the figure legends. Incuba- 
tions were at room temperature for 30 min. EMSAs were performed 
as previously described, using native 6% polyacrylamide g ls run in a 
Tris/glycine/EDTA buffer, pH 8.3 [4]. 
3. Results 
3. I. Receptor ecognition properties of  IRRP1, IRRP2 and 
IRRP3 
At the outset, studies were conducted to examine the recep- 
tor recognition characteristics of the IRRPs. We examined the 
influence of each of the IRRPs on [t25I]-IFN-c~2 binding to 
Daudi cells at 4°C. The results are shown in Fig. 1. Cells were 
incubated with the indicated oses of [~25I]-IFN-~2 in the pres- 
ence or absence of varying doses of the IRRPs. The experimen- 
tal conditions were such that the binding reaction reached a 
steady state equilibrium with respect o bound []251]-IFN. The 
amount of bound [~25I]-IFN at each input dose of [~25I]-IFN is 
designated 100%. The results demonstrate that each of the 
IRRPs will affect the binding capacity of the cells for the [~25I]- 
IFN by increasing the total amount of bound [t25I]-IFN. It is 
noteworthy that the IRRPs either alone, or in combination, do 
not compete with IFN-~2 for binding to the Daudi cells at 4°C. 
Similar results were obtained when the IRRPs were incubated 
together with [t25]-IFN-Con] (data not shown). When [J25I]- 
IFN-Con~ was cross-linked to cell surface receptors on Daudi 
cells, either in the presence or absence of each of the IRRPs, 
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Fig. 1. IRRPs increase the binding capacity of Daudi cells for IFN-~. 
5 x 105 Daudi cells were incubated for 2 h at +4°C with either 5 ng (A) 
or 10 ng (B) of [125I]-IFN-c~2, with or without he indicated concentra- 
tions of IRRPs. The values hown were obtained by subtracting non- 
specific counts/rain bound from total counts/rain bound. Non-specific 
binding was determinded in the presence of a 100-fold excess of unla- 
beled IFN. Each value represents the mean of triplicate cultures and 
exhibited a S.E.M. + 11%. 
then the cross-linked complexes eparated by SDS-PAGE, sim- 
ilar banding patterns were observed (Fig. 2). 
3.2. Influence of  lRRPs  on IFN-induced ISGF3 activation 
Since transcription factor activation is an early event that 
immediately follows the interaction between IFN and the re- 
ceptor complex, experiments were undertaken to examine the 
effect of IRRP treatment on IFN-induced ISGF3 activation in 
different cells. Cells were treated with IFN-Conj,  an IRRP, or 
a combination of IFN-Con~ and IRRP. Cell extracts were pre- 
pared and ISGF3 activation determined in the context of a shift 
in mobility of an ISRE in an electrophoretic gel shift assay. The 
results in Fig. 3A demonstrate that IRRP1, IRRP2 and IRRP3 
treatment of Daudi cells did not lead to ISGF3 activation. By 
contrast, IFN-Con] treatment of the same cells resulted in 
ISGF3 activation (Fig. 3A). However, when Daudi cells are 
treated with IFN-COnl together with either IRRP1 or IRRP2, 
the extent of ISGF3 activation is increased compared with the 
level of ISGF3 activation observed with IFN-COnl alone (Fig. 
3B). These results are consistent with the observation that these 
IRRPs increased receptor occupancy by IFN on these cells, i.e. 
receptor occupancy determines the extent of transcription fac- 
tor activation. 
MRC-5 cells exhibit a limited sensitivity to the antiviral ef- 
fects of IFNs-c~/fl. Sensitivity to the effects of IFN correlates 
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Fig. 2. IRRPs do not affect the affinity characteristics of [~25I]-IFN- 
Con I on Daudi cells. Covalent crosslinking of [125I]-IFN-Conl to Daudi 
cell surface receptors. Cells were incubated with 25 ng/ml of [~25I]- 
IFNCon~ in the presence or absence of 1/zg/ml each of IRRP1, IRRP2 
and IRRP3, at +4°C for 2 h, then bound IFN was crosslinked to the 
receptors and analyzed by SDS-PAGE and autoradiography. Positions 
of t4C-labeled molecualr weight markers, expressed in kDa, are shown. 
with the limited binding capacity of these cells for IFNs-~/fl, 
despite evidence for good cell surface expression of the two 
receptor chains IFNAR 1 and IFNABR, and the limited activa- 
tion of ISGF3 (unpublished observations, manuscript submit- 
ted). Since the preceding data would suggest hat the IRRPs 
enhance IFN-inducible activation of ISGF3, we examined 
whether IRRPI would have the same effect on MRC-5 cells. 
The results in Fig. 3C demonstrate hat IRRP1 treatment of 
MRC-5 cells enhances IFN-Con~-inducible ISGF3 activation. 
3.3. Influence of lRRPs on IFN-induced antiviral and growth 
inhibitory activities 
In the final series of experiments we examined the effects of 
IRRP treatment on IFN-induced biological activities. Fig. 4A 
describes the results obtained when human glial T98G cells are 
challenged with EMCV, either in the absence or presence of 
IFN-Conl and the IRRPs. The protective effects of sub-optimal 
doses of IFN-Con] on viral CPE are increased in the presence 
of IRRP1, IRRP2 and IRRP3. Each of the IRRPs confers no 
protection from viral infection when used alone. These results 
are in agreement with both the binding and signaling data: 
IRRP-mediated increases in IFN receptor occupancy leads to 
increased IFN-induced transcriptional activation and increased 
antiviral potency of the IFN. Earlier studies from this labora- 
tory have demonstrated that the extent of IFN-induced ISGF3 
activation correlates well with antiviral responses, yet is not 
linked to IFN-induced growth inhibition (manuscript submit- 
ted). Moreover, there is general agreement that the threshold 
dose for an IFN-induced growth inhibitory response is signifi- 
cantly higher than that for an antiviral response. Accordingly, 
we examined the influence of IRRP1 treatment on IFN-in- 
duced antiproliferative r sponses in the T98Gs, employing a
10-fold higher dose of IRRP1 than was used in the antiviral 
studies. The results in Fig. 4B show that IRRP1 marginally 
increase the growth inhibitory activity of IFN-Con~, under the 
prescribed conditions. The most pronounced effects were ob- 
tained when the lower doses of IFN were used. 
4. Discussion 
IFN-induced biological responses require the interaction be- 
tween IFN molecule(s) and the large, transmembrane multi- 
meric receptor complex. Although sites of interaction between 
ligand and receptor have not been assigned, an emerging con- 
sensus is that different faces of the IFN molecule interact with 
independent sites on the reeptors. Factors that contribute to- 
ward the affinity of the ligand for the multicomponent receptor 
system include the configuration of the receptor system and the 
association of specific janus kinases with the intracellular re- 
gions of the receptors. The overall avidity of complex formation 
depends on the crowding of receptors at the cell surfac and the 
flux of IFN molecules towards these receptors. Our working 
hypothesis has been that distinct receptor recognition domains 
on the IFN molecule interact with distinct contact sites on the 
receptor components. Low affinity interactions between indi- 
vidual recognition epitopes on the IFN molecule and single 
receptor sites are non-productive in terms of signal transduc- 
tion. The productive, high affinity binding paradigm we invoke 
would require simultaneous contacts between the different epi- 
topes on the IFN molecule and their associated receptor com- 
ponents. Thus, both receptor and ligand concentration contrib- 
ute toward the kinetics of interactions and determine the affin- 
ity of complex formation. To test this hypothesis we have syn- 
thesized a panel of peptides that correspond to putative recep- 
tor recognition domains in the IFN molecule. For a finite 
number of IFN receptors expressed at the surface of a given cell 
population, it should be possible to increase the binding capac- 
ity of these cells for whole IFN molecules by increasing the flux 
of contributing receptor binding peptides, thereby increasing 
the likelihood of successful simultaneous 'hits' on the receptors. 
Since the intact, native IFN molecule should be optimally con- 
figured to bind in the corresponding receptor pockets with high 
affinity characteristics, it is unlikely that individual peptides will 
compete for IFN-receptor site binding. 
In direct binding studies we measure a partition of the [125I]- 
IFN between the unbound/free state and the complexed/bound 
state on the cells. Our experimental conditions are set to meas- 
ure this partition when the binding reaction has reached equi- 
librium, i.e. steady state. For different [~25I]-IFN-~ input con- 
centrations we observed that the IRRPs increased the amount 
of bound [~25I]-IFN to cell surface receptors. Since the binding 
reactions are conducted at 4°C, the l igan~receptor complexes 
are not internalized, thus the number of receptors expressed at 
the surface of the cells is not reduced uring the course of the 
binding experiment. We infer, therefore, that the increase in 
binding capacity that we observed in the presence of the IRRPs 
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Fig. 3. Influence of IRRPs on IFN-induced ISGF3 activation. Daudi (A, B) and MRC-5 (C) cells were either left untreated or treated with 0.1 ng/ml 
(A), 0.016 ng/ml (B) or 1.0 ng/ml (C) IFN-Conl, in the presence or absence of 1/lg/ml of the IRRPs as indicated. 5/tg of whole cell extracts were 
reacted with 30,000 cpm of a 32p end-labeled ISRE, representing nucleotides -107 to -87 of the human 2-5A synthetase gene, which contains a 
functional ISRE. Complexes were resolved by using native gel electrophoresis and visualized by autoradiography. Mobility of ISGF3 is indicated. 
Specific omplexes were identified by the addition of a 100-fold excess of unlabeled ISRE (sp. comp.). A random hexapeptide (YVKRVK) was also 
included. The mobility of the free probe is shown. 
is a direct consequence of their influence on the avidity of the 
interaction between the IFN molecules and the cell surface 
receptors. The contributing effects of the IRRPs on IFN bind- 
ing most likely include reducing the dissociation of the ligand, 
and enhancing IFN-receptor affinity and receptor-receptor 
interactions. Since, in cross-linking experiments we have dem- 
onstrated that the IRRPs do not affect the nature of the multi- 
component IFN receptor complexes that form, these data sug- 
gest that the IRRPs may function to catalyse the formation of 
high affinity IFN-receptor complexes by increasing the number 
of low affinity receptor-ligand interactions necessary to initiate 
the cooperativity between receptor components. 
The results in Fig. 2 demonstrate hat the increase in receptor 
occupancy mediated by treatment with the different IRRPs 
results in enhanced activation of the cytoplasmic signaling fac- 
tor ISGF3. Since IRRP treatment alone was insufficient o 
activate signal transduction, these data suggest hat ligand- 
induced association of receptor components, that is a prerequi- 
site for activation of receptor-associated tyrosine kinases and/ 
or STAT proteins, involves the modification of multiple recep- 
tor sites. That is, the individual receptor components may inter- 
act with distinct domains of the IFN molecule, or IRRPs that 
correspond to these recognition epitopes, but functional activa- 
tion of the receptor equires that multiple receptor sites are 
ligand-bound to permit receptor components o complex. Ap- 
parently, even a combination of all 3 IRRPs will not facilitate 
receptor complexing. 
MRC-5 cells exhibit a poor binding capacity for IFNs-~/fl, 
that dictates the relatively weak sensitivity of these cells to the 
biological effects of IFNs. Based on our experimental results 
with the IRRPs, we investigated whether it would be possible 
to increase the sensitivity of MRC-5 cells to the effects of IFN 
by co-treatment with an IRRP. We provide evidence that ad- 
ministration of IRRP1 together with IFN-Con~ substantially 
increased the level of ISGF3 activation in MRC-5 cells above 
that attained with IFN alone. Moreover, we have shown that 
the effects of these IRRPs on IFN-induced responses are spe- 
cific, since a random hexapeptide did not affect the level of 
IFN-induced ISGF3 activation in Daudi cells (Fig. 2B), nor did 
BSA (data not shown). 
Consistent with their ability to potentiate receptor binding 
and ISGF3 activation effected by IFN, the IRRPs will increase 
the magnitude of the antiviral response induced by IFN. 
IRRP1 potentiation of the IFN-induced antiproliferative r - 
sponse was less marked. These data are consistent with obser- 
vations that the extent of IFN-induced ISGF3 activation di- 
rectly correlates with the magnitude of the IFN-induced antivi- 
ral response, yet does not equate with the extent of IFN-in- 
duced growth inhibition. Thus, modification of the IFN-recep- 
tor interaction by IRRP treatment, hat results in increased 
receptor occupancy, elicits an early post-receptor influence on 
signal transduction that ultimately results in an increased bio- 
logical response. Obviously, the challenge is to design specific 
IRRPs that maximally affect strategic biological responses, de- 
pendent on their modulation of specific receptor components. 
Preliminary indications are that IFNAR1 activation is tightly 
linked to signaling events that mediate an antiviral response 
and that IFNABR is the primary receptor binding component 
of the receptor complex. Studies are in progress to elaborate 
the specific amino acid clusters in the IFN molecule that inter- 
act directly with the extracellular regions of the different recep- 
tor chains. Utilising different IRRPs in combination with IFN 
we are examining the biological outcomes on cells that variably 
express the different Type 1 IFN receptor components at their 
surface. This approach will identify critical receptor recognition 
domains in the IFN molecule that interact with distinct recep- 
tor components. 
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